

Communication of the serendipity-mindsponge-3D knowledge management theory in Politico

 *Ruining Jin*

China University of Political Science and Law

<https://orcid.org/0000-0002-8542-7614>

November 15, 2022

Rare diseases, defined as “life-threatening or chronically debilitating diseases which are of such low prevalence that special combined efforts are needed to address them” [1], are serious threats that would impact millions of lives in the modern world [2]. During an interview with [Politico.eu](https://politico.eu), Ricardo Marek, a senior administrator of [Takeda](https://www.takeda.com/) (a biopharmaceutical multinational corporation headquartered in Japan; see <https://www.takeda.com/>), voiced his opinion regarding rare disease treatment [3].

SPONSORED CONTENT FROM TAKEDA

Europe's leadership in life sciences needs strong frameworks and partnerships

POLITICO Studio speaks with Ricardo Marek, President Europe and Canada at Takeda Pharmaceuticals, on why rare diseases need to be a public health priority, and how Europe can remain a leader in life sciences.



Marek [highlighted the importance of a policy framework that incentivizes investment in healthcare and partnership](#) to fight against it. In his vision, multistakeholder partnerships should be forged, and data and expertise sharing should be achieved following regulatory frameworks to accelerate the development of countermeasures against rare diseases. In addition, Marek addressed the significance of medicine and healthcare infrastructure innovation in improving diagnosis and providing healthcare management and treatment options to these rare disease patients.

In endorsing such regulatory frameworks and innovation, Marek referred to a recent publication of SM3D Portal founders regarding global partnership and cooperation during COVID-19 vaccine production [4]. This marks a remarkable milestone when [the serendipity-mindsponge-3D knowledge management theory](#) is directly communicated through a well-known media channel like Politico.

POLITICO

Figure: Logo of Politico ([Public Domain](#))

Politico (est. in 2007), a political journalism newspaper company, covers politics and policy in the United States and around the world. According to a third-party survey of 249 Brussels influencers, [Politico.eu](https://www.politico.eu) is the most widely read news organization [5].

References

- [1] European Commission. (2009). Useful Information on Rare Diseases from an EU Perspective. https://ec.europa.eu/health/ph_information/documents/ev20040705_rd05_en.pdf
- [2] Wakap SN, et al. (2020). Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. *European Journal of Human Genetics*, 28(2), 165-173.
- [3] Politico Studio. (2022, Oct. 27). Europe's leadership in life sciences needs strong frameworks and partnerships. *Politico*. <https://www.politico.eu/sponsored-content/europes-leadership-in-life-sciences-needs-strong-frameworks-and-partnerships/>
- [4] Vuong QH, et al. (2022). Covid-19 vaccines production and societal immunization under the serendipity-mindsponge-3D knowledge management theory and conceptual framework. *Humanities and Social Sciences Communications*, 9, 22. <https://www.nature.com/articles/s41599-022-01034-6>
- [5] David U. (2016). What a major leadership change means for Politico's global ambitions. *Columbia Journalism Review*. <https://www.cjr.org/analysis/politico.php>

